GB2583526A — Use of cannabidiol in the treatment of tuberous sclerosis complex

USPTO Abstract

A cannabidiol (CBD) preparation for use in the treatment of seizures associated with tuberous sclerosis complex (TSC). Preferably the CBD used is in the form of a botanically derived purified CBD which comprises greater than or equal to 98% (w/w) CBD and less than or equal to 2% (w/w) of other cannabinoids. The other cannabinoids present are THC at a concentration of less than or equal to 0.1% (w/w); CBD-C1 at a concentration of less than or equal to 0.15% (w/w); CBDV at a concentration of less than or equal to 0.8% (w/w); and CBD-C4 at a concentration of less than or equal to 0.4% (w/w). The botanically derived purified CBD preferably also comprises a mixture of both trans-THC and cis-THC. Alternatively, a synthetically produced CBD is used. In use the CBD is given concomitantly with one or more other anti-epileptic drugs (AED). Alternatively, the CBD may be formulated for administration separately, sequentially or simultaneously with one or more AED or the combination may be provided in a single dosage form.